Bladder Cancer Clinical Trial
— Bladder CancerOfficial title:
Intravesical AD 32 (Valrubicin) in Patients With Carcinoma in Situ (CIS) of the Bladder Who Have Failed or Have Recurrence Following Treatment With Bacillus Calmette-Guerin (BCG)
Verified date | June 2015 |
Source | Endo Pharmaceuticals |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
This is a Phase II/Phase III study of intravesical AD 32 (valrubicin) in patients with carcinoma in situ (CIS) who have been previously treated with intravesical Bacillus Calmette-Guerin (BCG) for CIS and in whom recurrence or failure has occurred after multiple courses of intravesical treatment.
Status | Completed |
Enrollment | 90 |
Est. completion date | April 1997 |
Est. primary completion date | April 1997 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion- 1. Patients must have pathologically-proven CIS with no evidence of muscle invasive disease. 2. Patients with concurrent Ta or T1 papillary tumors are eligible provided papillary tumor(s) are resected prior to study treatment. Cystoscopic evaluation and, if indicated, transurethral resection of bladder tumor (TURBT) must be performed within 28 days of study treatment. 3. Patients must have received at least two or more prior courses of intravesical therapy for CIS per the recommended schedules. BCG must have been one of the prior therapies administered. Patients can have either failed BCG therapy or have been successfully treated with BCG, but subsequently found to have recurrence. The standard course of intravesical therapy must include six weekly treatments (allowable range of instillations per course is 4-9). 4. Patients must have a positive urine cytology at baseline (<28 days) prior to the first AD 32 (valrubicin) treatment. Patients with papillary lesions must have a positive cytology following TURBT or have a baseline cytology that was negative or equivocal and histologic confirmation of CIS. 5. Patients must have an ECOG performance status of 0-2 and a life expectancy of at least 6 months. Exclusion- 1. Patients with urogenital tumors with histology other than transitional cell carcinoma 2. Patients with residual papillary disease at the time of study treatment. 3. Patients with a history of other primary malignancy (other than squamous or basal cell skin cancers) within the last 5 years. 4. Patients with evidence of muscle invasive disease (stage higher than T1). 5. Patients with any previous intravesical treatment with AD 32 (valrubicin). 6. Patients with any intravesical therapy within 28 days prior to first AD 32 (valrubicin) treatment. 7. Patients with a plan to receive other concurrent therapy for treatment of primary treatment tumor during participation in this study. 8. Patients who had received prior systemic or radiation therapy for bladder cancer. 9. Women who were pregnant or lactating. Individuals of reproductive potential could not participate unless agreeing to use an effective contraceptive method for themselves and/or their sexual partners. 10. Patients who, in the investigator's opinion, could not comply with the provisions of the protocol or did not understand the nature of the study. 11. Patients who, in the opinion of the investigator, could not tolerate intravesical administration of approximately 75 mL of fluid or who could not tolerate surgical manipulation (cystoscopy, mapping biopsies, barbotage) due to the presence of concomitant serious illnesses (ie, uncontrolled cardiac or respiratory disorders). |
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Stacy Childs, MD | Alabaster | Alabama |
United States | Hugh Fisher, MD | Albany | New York |
United States | Steohen Hardeman, MD | Austin | Texas |
United States | Harold Frazier, MD | Bethasda | Maryland |
United States | John Libertino | Burlington | Massachusetts |
United States | Michael Wolff, MD | Burlington | North Carolina |
United States | Charles Brendler, MD | Chicago | Illinois |
United States | Patrick Guinan, MD | Chicago | Illinois |
United States | Eric Klein, MD | Cleveland | Ohio |
United States | B. Thomas Brown, MD | Daytona Beach | Florida |
United States | Cary Robertson, MD | Durham | North Carolina |
United States | Jeffrey Ignatoff, MD | Evanston | Illinois |
United States | Charles Jackson, MD | Ft. Lauderdale | Florida |
United States | Ian Thompson, MD | Ft. San Houston | Texas |
United States | Myron Murdock, MD | Greenbelt | Maryland |
United States | Seth Lemer, MD | Houston | Texas |
United States | W. Lamar Weems, MD | Jackson | Mississippi |
United States | William Friedel, MD | La Mesa | California |
United States | David Wood, MD | Lexington | Kentucky |
United States | John Tuttle, MD | Lexington | Kentucky |
United States | Marc Soloway, MD | Miami | Florida |
United States | Richard Boxer, MD | Milwaukee | Wisconsin |
United States | L. Dean Knoll, MD | Nashville | Tennessee |
United States | Stephen Auerbach, MD | Newport Beach | California |
United States | William Bohnert, MD | Phoenix | Arizona |
United States | Jeffrey Cohen, MD | Pittsburgh | Pennsylvania |
United States | Bruce Lowe, MD | Portland | Oregon |
United States | Jacques Susset, MD | Providence | Rhode Island |
United States | Aaron Katz, MD | Richmond | Virginia |
United States | Gary Katz, MD | Richmond | Virginia |
United States | Michael Blute, MD | Rochester | New York |
United States | William Moseley, MD | San Diego | California |
United States | Standley Brosman, MD | Santa Monica | California |
United States | Scott Swanson, MD | Scottsdale | Arizona |
United States | Williams Ellis, MD | Seattle | Washington |
United States | Dennis Venable, MD | Shreveport | Louisiana |
United States | Bruce Dalkin, MD | Tucson | Arizona |
United States | Donald Gleason, MD | Tucson | Arizona |
United States | Eugene Dula, MD | Van Nuys | California |
Lead Sponsor | Collaborator |
---|---|
Endo Pharmaceuticals |
United States,
Steinberg G, Bahnson R, Brosman S, Middleton R, Wajsman Z, Wehle M. Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J Urol. 2000 Mar;163(3):761-7. Erratum in: J Urol. 2008 Jan;179(1):386. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Assess the efficacy of AD 32 (valrubicin) in patients with CIS of the bladder who previously have been treated with BCG for CIS and in whom recurrence or failure had occurred after multiple courses of intravesical treatment. | 12 weeks | No | |
Secondary | To evaluate the qualitative toxicities associated with intravesical therapy using AD 32 (valrubicin). | 6 weeks | Yes | |
Secondary | To determine the concentration of anthracyclines in the voided urine of patients who chose to participate in a urine recovery study. | 6 weeks | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06034015 -
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of APL-1501 Extended Release (ER) Capsules Compared to APL-1202 Immediate Release (IR) Tablets in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04235764 -
En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device
|
||
Completed |
NCT02371447 -
VPM1002BC in Recurrent Non-muscle Invasive Bladder Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT04081246 -
Transurethral Modified En Bloc Resection For Large Bladder Tumours.
|
N/A | |
Recruiting |
NCT06059547 -
Neoadjuvant Immunotherapy in Combination With the Anti-GDF-15 Antibody Visugromab (CTL-002) for Treatment of Muscle Invasive Bladder Cancer
|
Phase 2 | |
Terminated |
NCT04779489 -
Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder Cancer
|
N/A | |
Not yet recruiting |
NCT04493489 -
Propranolol Adjuvant Treatment of Bladder Cancer
|
Phase 2 | |
Completed |
NCT03520231 -
Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases
|
Phase 2 | |
Recruiting |
NCT04537221 -
Nordic Cystectomy Study III - Transfusion
|
||
Withdrawn |
NCT03007771 -
Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia
|
Phase 1 | |
Completed |
NCT01955408 -
Severity of Overactive Bladder Symptoms in Patients After Synergo Treatment
|
N/A | |
Completed |
NCT04487457 -
Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy
|
||
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT05562791 -
A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer
|
Phase 1 | |
Completed |
NCT00199849 -
NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine
|
Phase 1 | |
Completed |
NCT02781428 -
To Detect the Sensitivity of the UroMark Assay
|
||
Recruiting |
NCT04738630 -
Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer
|
Phase 2 | |
Completed |
NCT03980041 -
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
|
Phase 2 | |
Active, not recruiting |
NCT03978624 -
Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer
|
Phase 2 | |
Completed |
NCT04534309 -
Behavioral Weight Loss Program for Cancer Survivors in Maryland
|
N/A |